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Purpose: To quantify the 2-year success rate and complications of trabeculectomy with adjunctive
mitomycin C (MMC).
Methods: A retrospective chart review was undertaken of 147 eyes that had undergone trabeculectomy
with adjunctive MMC (concentration from 0.1 to 0.27 mg/mL) and at least 2 years’ follow-up between
January 2001 and March 2010. Demographic and clinical data were collected from all patients at the
time of surgery and subsequent follow-up visits. Complete success was deﬁned as intraocular pressure
(IOP)  21 mmHg without any additional medication, whereas qualiﬁed success was deﬁned as IOP
21 mmHg with or without medication.
Results: At 24 months, mean IOP was 16.4  10.6 mmHg, with a mean IOP decrease of 19.8  14.2 mmHg.
In primary glaucoma patients (n ¼ 66), 60.6% and 95.4% of eyes achieved complete success and qualiﬁed
success, respectively, at 2-year follow-up. Sub-group analysis of the initial trabeculectomy in primary
glaucoma patients (n ¼ 49) showed that complete and qualiﬁed success increased to 65.3% and 98.0%,
respectively. The success rate was lower in secondary glaucoma patients (n ¼ 74), with complete success
at 41.9% and qualiﬁed success at 67.6% at 2-year follow-up. Eighty-six eyes (58.5%) developed one or more
complications, from mild, such as hyphema, to severe, such as bleb leakage, which could necessitate
surgical intervention. Twenty-six eyes developed severe complications, such as wound gap after 5
postoperative days, hypotony, hypotony maculopathy, choroidal detachment, overhanging bleb, bleb
leakage, and endophthalmitis. A comparison between eyes with severe complications and other eyes in
relation to different MMC amount, deﬁned as MMC concentration multiplied by application duration,
revealed no signiﬁcant difference (p ¼ 0.136). Further glaucoma surgery was performed in 27 eyes
(18.4%).
Conclusion: The outcome of trabeculectomy with low-dose intraoperative MMC is favorable in primary
glaucoma patients at 2-year follow-up. Severe complications are not signiﬁcantly related to MMC
amount. Factors associated with severe complications require further study. Careful selection of MMC
concentration and application time based on preoperative and intraoperative risk factors may further
improve surgical results.
Copyright  2012, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Glaucoma is a multifactorial optic neuropathy with a character-
istic acquired atrophy of the optic nerve and loss of retinal ganglion
cells and their axons, resulting in characteristic visual ﬁeldmology, Kaohsiung Medical
07, Taiwan.
).
e Ophthalmologic Society of Taiwabnormalities. Although many hemodynamic factors, such as
ocular blood ﬂow and ocular perfusion pressure,1e3 have been re-
ported to be associated with development of glaucoma, intraocular
pressure remains, to date, the only factor modiﬁable through
different treatment modalities, such as topical eye drops, laser
procedure, and surgical intervention. Surgery is indicated when
maximum tolerated medications and laser therapy fail to control
the progression of glaucomatous optic neuropathy.
Since its introduction by Cairns4 in 1968, trabeculectomy has
been the most commonly used ﬁltrating surgical treatment. Thean. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Preoperative risk assessment of surgical failure.






Previous intraocular surgery involving
conjunctiva (e.g., ECCE, failed
glaucoma ﬁltering surgery, etc.)





Previous intraocular surgery not
involving conjunctiva (e.g.,
phacoemulsiﬁcation, etc.)
AACG ¼ acute angle closure glaucoma; CACG ¼ chronic angle closure glaucoma;
ECCE ¼ extracapsular cataract extraction; IOP ¼ intraocular pressure;
PK ¼ penetrating keratoplasty; POAG ¼ primary open angle glaucoma.
C.-Y. Huang et al. / Taiwan Journal of Ophthalmology 3 (2013) 31e3632success of trabeculectomy surgery depends on producing
a controlled, scar-limited ﬁstula stable enough to maintain
adequate aqueous outﬂow. Factors associated with an increased
risk of bleb failure include young age, aphakia, anterior segment
neovascularization, inﬂammation, previously failed glaucoma
ﬁltering surgery,5,6 and prolonged exposure to ocular hypotensive
agents.7,8 Thus, to enhance surgical success, pharmacologic
modulation of wound healing, such as treatment with 5-
ﬂuorouracil and mitomycin C (MMC) during and after glaucoma
ﬁltration surgery, has been investigated since the early 1980s. MMC
is an antibiotic isolated by Hata et al9 from Streptomyces caespitosus
in 1956 and classiﬁed as an alkylating agent with antiproliferative
activity. The initial application of MMC in ophthalmology was
introduced by Kunitomo and Mori10 in 1963 for an adjuvant
therapy following pterygium surgery for the prevention of recur-
rence. Later, Chen ﬁrst applied adjunctive MMC during trabecu-
lectomy and achieved favorable results for an eye with corneal
leukoma and traumatic glaucoma that had undergone penetrating
keratoplasty and two unsuccessful glaucoma surgeries.11 Beginning
in 1981, more surgical results with concurrent MMC application
during trabeculectomy were collected by Chen et al as the basis of
the ﬁrst clinical report,12 which inspired much of the later labora-
tory work on and clinical application of the effectiveness of MMC.
Several randomized controlled trials of intraoperative MMC
compared to placebo or no adjunct in trabeculectomy surgery
revealed a reduction of the relative risk of surgical failure.13e16
Complications reported in the trials included wound leaks,
choroidal effusions, suprachoroidal hemorrhage, hypotony,
hyphema, and cataract.6,13e16 Cystic, avascular blebs usually
developed with intraoperative MMC administration. Such blebs
may lead to overhanging on the cornea and necessitate bleb revi-
sion to prevent late bleb leakage and subsequent bleb infection.17
The aim of this report is to quantify the success rate and
complications of trabeculectomy with adjunctive MMC.
2. Methods
This is a retrospective case series. The research followed the
tenets of the Declaration of Helsinki. The study was approved by
the ethics committee of the KaohsiungMedical University Hospital.
The records of patients who had received trabeculectomy with
adjunctive MMC by two glaucoma specialists (K.Y.W., H.Y.T.)
between January 2001 and March 2010 at Kaohsiung Medical
University Hospital were retrospectively reviewed. Patients with
a follow-up period of less than 2 years, insufﬁcient hospital records,
signiﬁcant ocular disease other than glaucoma, or concurrent
cataract surgery were not included in this study. Baseline demo-
graphic data and clinical characteristics have been recorded,
including patient age, sex, type of glaucoma, number of ocular
hypotensive medications, duration of glaucoma, preoperative
intraocular pressure, cup/disk ratio, and best-corrected visual
acuity.
2.1. Surgical technique
After a limbal-based or fornix-based conjunctival ﬂap was
created, the Tenon’s capsule was dissected and adequate cautery
applied. A sponge soaked in MMC was placed under the conjunc-
tival ﬂap and removed after 1 minute. The process was repeated for
the desired soaking duration. The areawas then irrigated copiously
with balanced salt solution. MMC concentration and application
time were determined on the basis of preoperative risk factors
(Table 1) and intraoperative ﬁndings regarding the thickness of the
Tenon’s capsule and scar from previous surgery. Conditions such as
neovascular glaucoma, uveitic glaucoma, iridocorneal endothelialsyndrome, postpenetrating keratoplasty glaucoma, traumatic
glaucoma, and previous intraocular surgery involving conjunctiva
(e.g. extracapsular cataract extraction, failed glaucoma ﬁltering
surgery) were categorized as factors associated with relatively
higher risks of surgical failure and required a higher concentration
of MMC. Chronic use of topical intraocular pressure (IOP)-lowering
agents, steroid-induced glaucoma, primary glaucoma (including
primary open angle glaucoma, and acute and chronic angle closure
glaucoma), and previous intraocular surgery not involving
conjunctiva (e.g. phacoemulsiﬁcation) were categorized as factors
associated with relatively lower risk of failure and required a lower
concentration of MMC. Thus, the concentration used frequently in
our practice is 0.1e0.2 mg/mL for low-risk patients and 0.2e
0.27 mg/mL for higher-risk patients; it is applied with variable
duration (1e3 minutes). A half thickness, trapezoid scleral ﬂap
with bases of 4 mm and 2.5 mm and a height of 2.5 mm was
dissected. Additional MMC soaking (duration 1e2 minutes) under
the partial thickness scleral ﬂap was performed if necessary. Deep
sclerectomy including derooﬁng of the Schlemm’s canal was con-
ducted. A block of sclera bed including trabecular meshwork was
removed with a trabeculectomy punch, followed by a peripheral
iridectomy. The scleral ﬂap was sutured with 10-0 nylon using the
releasable suture method. The conjunctival ﬂap was closed with
a 10-0 nylon running suture.
Postoperative data, including IOP, number of ocular hypotensive
medications used, and bleb appearance, were collected at 1 month,
3 months, 6 months, 12 months, 18 months, and 24 months. The
size of bleb with maximum diffusion area was graded according to
the extent of clock-hour area. Any intraoperative or postoperative
complications, such as hyphema, ﬂat anterior chamber, wound
leakage, hypotony (deﬁned as IOP <6 mmHg), hypotony macul-
opathy, choroidal detachment, bleb leakage, blebitis, endoph-
thalmitis, and any additional surgery, were recorded.
Complete success was deﬁned as IOP 21 mmHg without any
additional medication, whereas qualiﬁed success was deﬁned as
IOP 21 mmHg with or without medication. Failure was deﬁned as
uncontrolled IOP despite medical treatment, or when an additional
intervention (such as bleb revision, repeat trabeculectomy, or diode
laser cyclodestruction) was required. The exact time of the occur-
rence of any failures was recorded.
Statistical analysis was performedwith SPSS statistical software,
version 17.0, for Windows (SPSS Inc, Chicago, IL, USA). Preoperative
and postoperative IOP and the number of ocular hypotensive
medications were analyzed using a paired t test. Categorical data
were analyzed using the Pearson c2 or Fisher’s exact test. The
probability of continued success with time after surgery was esti-
mated using KaplaneMeier analysis and survival curves were
drawn. The signiﬁcance level of the difference between primary
and secondary glaucoma patients in the KaplaneMeier survival
curves was calculated with the log-rank test. A p-value of 0.05
was considered signiﬁcant.
Table 3
Preoperative and postoperative clinical data.
Preoperative 1 y 2 y Final visit
IOP (mmHg) 36.5  14.5 15.0  9.8* 16.4  10.6* 19.5  13.2*
No. of medications 3.7  0.8 0.9  1.2* 1.0  1.3* 1.5  1.6*
Bleb size d 2.2  1.2 2.0  1.2 1.6  1.2
Bleb vascularity
Vascular d 36% 35% 41%
Mixed vascular and
avascular
d 6% 9% 7%
Avascular d 58% 56% 52%
Data expressed as mean  standard deviation or %; Paired t-test used to calculate
signiﬁcance; *p < 0.001.
d ¼ no data available; IOP ¼ intraocular pressure.
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Outcome clinical data analysis was performed on 147 eyes of
128 patients, of whom 68 (53.1%) were male and 60 (46.9%) were
female. Demographic data of study population are summarized in
Table 2. Mean preoperative IOP was 36.5  14.5 mmHg under
3.7  0.8 ocular hypotensive medications. Preoperative fundus
examination revealed cup/disc ratios of 0.3e1.0 (mean, 0.81). The
mean follow-up period of the ﬁnal visit was 46.9 months (range,
24e131 months).
The concentration of MMC varied from 0.1 mg/mL to 0.27 mg/
mL, and exposure time varied from 1 minute to 5 minutes. Six eyes
(4%) received the MMC concentration of 0.27 mg/mL, 94 eyes (64%),
42 eyes (29%), and ﬁve eyes (3%) received 0.2 mg/mL, 0.13 mg/mL,
and 0.1mg/mL ofMMC, respectively. MMCwas soaked either under
the subconjunctival ﬂap or under the subconjunctival and sub-
scleral ﬂap. A total of 131 eyes (89%) received 3 minutes of MMC
soaking under the subconjunctival ﬂap; among these, 86 eyes, 15
eyes, and 30 eyes received subconjunctival soaking only, subcon-
junctival soaking and another 1 minute of subscleral soaking, and
subconjunctival soaking and another 2 minutes of subscleral
soaking, respectively. The remainder (16 eyes, 11 %) received 1e2
minutes of MMC soaking under the subconjunctival ﬂap and 0e2
minutes of MMC soaking under the subscleral ﬂap.
At 12 months, mean IOP was 15.0  9.8 mmHg, with a mean IOP
decrease of 21.0  15.0 mmHg. At 24 months, mean IOP was
16.4 10.6 mmHg, with a mean IOP decrease of 19.8  14.2 mmHg.
At the ﬁnal follow-up visit, mean IOP was 19.5  13.2 mmHg, with
a mean IOP decrease of 16.7 15.2 mmHg. The requirement for IOP
lowering agents fell from a mean of 3.7/patient to 1.5/patient at theTable 2
Demographic data of study population (n ¼ 147).
Characteristics Mean  SD
(range) or n (%)
Age (y) (n ¼ 128) 51.2  16.8 (0.4e81.1)









Neovascular glaucoma 38 (25.97%)
Uveitic glaucoma 13 (8.8%)
ICE syndrome 11 (7.5%)
Steroid-induced glaucoma 5 (3.4%)
Post-PK glaucoma 5 (3.4%)
Traumatic glaucoma 2 (1.4%)
Childhood glaucoma 7 (4.8%)
Glaucoma duration
Unknown 9 (6.1%)
<3 years 80 (54.4%)
3 years 58 (39.5%)
Initial or repeat trabeculectomy
Initial 113 (76.9%)
Repeat 34 (23.1%)
Intraocular pressure (mmHg) 36.5  14.5 (9e89)
Number of ocular hypotensive agents 3.7  0.8 (2e5)





AACG ¼ acute angle closure glaucoma; CACG ¼ chronic angle closure glaucoma;
ICE ¼ iridocorneal endothelial; PK ¼ penetrating keratoplasty; POAG ¼ primary
open angle glaucoma; SD ¼ standard deviation.ﬁnal visit (Table 3). Bleb size and vascularity condition in different
time periods are summarized in Table 3.
In primary glaucoma patients (n ¼ 66), 60.6% and 95.4% of eyes
achieved complete success and qualiﬁed success (as deﬁned above),
respectively, at 24-month follow-up. Sub-group analysis of the
initial trabeculectomy in primary glaucoma patients (n ¼ 49)
showed that complete and qualiﬁed success increased to 65.3% and
98.0%, respectively. The success rate was lower in secondary glau-
coma patients (n¼ 74), with complete success at 41.9% and qualiﬁed
success at 67.6% at 24-month follow-up (Table 4). KaplaneMeier
survival analysis with a log-rank test (p < 0.001; Fig. 1) showed
that primary glaucoma patients had a greater probability of success
than secondary glaucoma patients.
Eighty-six eyes (58.5%) developed one or more complications
from mild to severe (Table 5). Fifty eyes (34.0%) developed
hyphema; in 45 of these, the condition subsided after 1e17 days.
The hyphema lasted longer in two eyes (8 and 28 months), which
experienced complete recovery. Persistent hyphema with eventual
cornea leukoma developed in one eye. Two eyes with hyphema
required reoperation for surgical failure. These ﬁve eyes with either
longer duration of hyphema or a failed bleb all belonged to neo-
vascular glaucoma patients.
One eye with intraoperative conjunctiva button hole sutured
during operation developed bleb leakage postoperatively. The leak
spontaneously healed after 2 weeks without further intervention.
Flat anterior chamber developed in 25 eyes (17.0%), with Grade 1
ﬂat chamber (peripheral-iridocorneal touch) in 20 eyes, and Grade
2 ﬂat chamber (pupillary-corneal touch) in ﬁve eyes. No Grade 3 ﬂat
chamber (lens-corneal touch) developed. Only one eye required
revision for persistent hypotony. The other 24 eyes had complete
recovery in less than 11 days.
Conjunctival wound gap developed in 22 eyes (15.0%), with
leakage in 13 eyes. Only one eye required suture for leaking wound.
The wounds of the other 21 eyes spontaneously healed after 1e45
days.
Hypotony (IOP < 6 mmHg) without maculopathy developed in
one eye, which experienced recovery after 12 days. Hypotony
maculopathy and choroidal detachment developed in seven eyes
(4.8%) and four eyes (2.7%), respectively. Maculopathy lasted in one
eye for more than 10 years and in two eyes for more than 2 years.
In the other eyes with maculopathy, the condition subsided after
1 day to 2 months without further intervention. One eye with
choroidal detachment received bleb revision for persistent hypot-
ony. Choroidal detachment subsided in one eye after oral steroid,
and in two eyes without any treatment.
One of the two eyes with overhanging bleb required bleb revi-
sion due to leakage. Bleb leakage developed in ﬁve eyes (3.4%). The
leakage stopped spontaneously after 1 day in one eye, and persisted
for more than 2 years in another eye. Two eyes received bleb
revision and one eye developed endophthalmitis. Cataract
Table 4
Success and failure rate at follow-up visits.
Primary glaucoma Secondary glaucoma Childhood glaucoma
n ¼ 66 n ¼ 74 n ¼ 7
1 y 2 y Final 1 y 2 y Final 1 y 2 y Final
Complete success 71.2% 60.6% 57.6% 43.2% 41.9% 36.5% 28.6% 28.6% 28.6%
Qualiﬁed success 97% 95.4% 86.4% 74.3% 67.6% 60.8% 71.4% 71.4% 71.4%
Failure 3% 4.5% 13.6% 25.7% 32.4% 39.2% 28.6% 28.6% 28.6%
C.-Y. Huang et al. / Taiwan Journal of Ophthalmology 3 (2013) 31e3634progressionwith extractionwithin 1 year after trabeculectomy was
noted in three eyes (2.0%).
Further glaucoma surgery was performed in 27 eyes (18.4%). Ten
eyes received cyclophotocoagulation, and 17 eyes received bleb
revision or repeat trabeculectomy.4. Discussion
Initially, MMC is used for patients with high risk of failure, such
as those with young age, aphakia, anterior segment neo-
vascularization, inﬂammation, and previously failed glaucoma
ﬁltering surgery, and is used less in primary glaucoma patients. Due
to the greater number of ocular hypotensive medication options
and the report from the Collaborative Initial Glaucoma Treatment
Study that medical therapy was essentially equally as effective as
surgical therapy in preventing glaucomatous visual ﬁeld progres-
sion,18 patients requiring surgery have usually received topical
ocular hypotensivemedications for a long time. Exhaustive medical
therapy increases the number of conjunctival and subconjunctival
inﬂammatory cells, and enhances the risk of external bleb scarring
and ﬁltration surgery failure.7 That is the reason for almost all types
of glaucoma patients in our practice, including primary and
secondary or repeated surgery cases, receiving concurrent MMC
application during trabeculectomy.
In our practice, the majority of cases (89%) received 3minutes of
MMC soaking under the subconjunctival ﬂap. If risk of internal
block was presenteddfor example, neovascular glaucoma, uveitic
glaucoma, or iridocorneal endothelial syndromedan additional 1e
2 minutes of MMC soaking under the subscleral ﬂap was per-
formed. In an in vitro study,19 ﬁbroblasts cultured Tenon’s capsules
from human individuals aged 20e45 years were shown to tolerate
MMC better than those cultured from younger (age <20 years) orFig. 1. Kaplan-Meier survival analysis of qualiﬁed success rates of intraocular pressure
control in primary and secondary glaucoma patients.older (age >45 years) groups. Because the younger and older eyes
are more sensitive toMMC, less exposure is recommended. Thus, in
our experience, MMC concentration and application time is
decreased for patients under 20 or over 60.
The concentration ofMMC used by Chen for refractory glaucoma
patients was 0.1e0.4 mg/mL for 5 minutes.12 In the literature, the
concentration of MMC and application time are usually reported to
be 0.1e0.5 mg/mL and 1e5 minutes, respectively.13e15,20,21 Severe
complications, such as hypotony, choroidal detachment, thin bleb,
or overhanging bleb with subsequent leakage and blebitis or
endophthalmitis, may be aggravated with concurrent MMC appli-
cation.13,14,22,23 These complications may be highly correlated to
MMC concentration and application time.12,20 Hence, we used
a relatively low concentration of MMC (0.1e0.2 mg/mL) and 1e4
minutes application time for the majority of cases to prevent
potentially severe complications and obtain favorable surgical
results; these results were 60.6% complete success and 95.4%
qualiﬁed success at 24-month follow-up in primary glaucoma
patients. This is comparable to a prospective study that achieved
a 96.6% success rate (IOP < 18 mmHg) at 1-year follow-up.15 In
secondary glaucoma, we used a relatively high concentration of
MMC (0.2e0.27 mg/mL) and 3e5 minutes application time, and
achieved complete and qualiﬁed success rates of 41.9% and 67.6%,
respectively, at 2-year follow-up. This is comparable to a retro-
spective study of 68 patients with high-risk characteristics for
failure who received trabeculectomy with MMC. In that study,
Perkins et al reported a 59% rate of complete success and 75% rate of
qualiﬁed success based on the same aforementioned criteria at 2-
year follow-up.23
In our practice, 86 eyes (58.5%) developed one or more
complications, such as hyphema, button hole, ﬂat chamber, wound
gap with or without leakage, hypotony with or without maculop-
athy, choroidal detachment, overhanging bleb, bleb leakage, cata-
ract progression, and endophthalmitis. Of these complications,
button hole and wound gap within 5 postoperative days are
considered to be surgical technique-related.Table 5
Intraoperative and postoperative complications.
Complications No. (%)
Hyphema 50 (34.0%)
Button hole 1 (0.7%)
Flat chamber
Grade 1 20 (13.6%)
Grade 2 5 (3.4%)
Grade 3 0 (0%)
Wound gap without leakage 9 (6.1%)
Wound gap with leakage 13 (8.8%)
Hypotony without maculopathy 1 (0.7%)
Hypotony with maculopathy 7 (4.8%)
Choroidal detachment 4 (2.7%)
Overhanging bleb 2 (1.4%)
Bleb leakage 5 (3.4%)
Cataract progression* 3 (2.0%)
Endophthalmitis 1 (0.7%)
* Received cataract operation within 1 year after trabeculectomy.
Table 6
Eyes with or without severe complication and different mitomycin C exposure
amount.
MMC amount (mg/mL  min)
<0.4 0.4e0.6 >0.6
No or mild complication (n ¼ 121) 12 (10%) 66 (55%) 43 (35%)
Severe complication (n ¼ 26) 1 (4%) 20 (77%) 5 (19%)
Fisher’s exact test, p ¼ 0.136.
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these, 26 were neovascular glaucoma prone to hyphema develop-
ment. If we ignore these cases of hyphema, which is inevitable in
neovascular glaucoma patients, the overall complication rate is
40.8% (60 eyes). Five eyes with either longer duration of hyphema
(8 and 28 months) or a failed bleb all belonged to neovascular
glaucoma patients. In 45 eyes, including those of 21 neovascular
glaucoma patients, these conditions subsided within 17 days. The
development of hyphema was associated with surgery and the
disease entity itself and not related to MMC application.
The releasable suture method helps decrease the chance of
postoperative overﬁltration, which may result in hypotony or ﬂat
chamber. Flat anterior chamber developed in 25 eyes (17.0%), with
Grade 1 ﬂat chamber in 20 eyes and Grade 2 ﬂat chamber in ﬁve
eyes. Only one eye required revision for persistent hypotony. The
other 24 eyes completely recovered in less than 11 days.
Conjunctival wound gap developed in 22 eyes (15.0%), but with
leakage in only 13 eyes. Of these 22 eyes, leakage in four eyes
occurred within 5 days postsurgery, and 10 eyes developed leakage
after the conjunctival suture was removed. Only one eye required
suture for a leaking wound, which occurred 14 days postoperation
and 4 days after removing the sutures. This may be strongly related
to MMC-delayed wound healing. Wound gap occurring during the
ﬁrst 5 postoperative days is thought to be suture technique-related.
After 5 days, the inhibitory effect of wound healing by MMC is
a possible factor of wound gap. Thewound gaps of the other 21 eyes
spontaneously healed after 1e45 days.
Eleven eyes (7.5%) developed hypotony without maculopathy,
hypotony with maculopathy, or choroidal detachment. The MMC
concentration used was 0.27 mg/mL in one eye, 0.2 mg/mL in four
eyes, and 0.13 mg/mL in six eyes. Hypotony maculopathy, ﬁrst
described in 1954 by Dellaporta, usually occurs after glaucoma
surgery or after perforating eye injuries. MMC reduces resistance to
aqueous outﬂow normally resulting from postoperative subcon-
junctival ﬁbrosis, and it is possible that hypotony developed more
frequently after trabeculectomy with MMC than after standard
trabeculectomy. Hypotonymaculopathy has been reported to occur
in 3e20% of cases of trabeculectomy augmented with MMC.24e28
Some studies have suggested that high concentrations of MMC or
increased exposure time may be associated with the development
of hypotony maculopathy.29e31 Causes of hypotony after trabecu-
lectomy include wound leakage, overﬁltration, surgical cyclo-
dialysis, and MMC-induced toxicity of the ciliary body.32
Cyclodialysis and early wound leakage may be associated with
surgical technique, while late wound leakage, overﬁltration, and
toxicity of the ciliary body may be related to MMC application.
Releasable sutures or tighter scleral ﬂap suturing with post-
operative laser suture lysis should be used in order to avoid over-
ﬁltration and the occurrence of hypotony maculopathy.33e35
MMC application during glaucoma ﬁltering surgery often leads
to the development of thin-walled, avascular blebs. Such blebs may
lead to low outﬂow resistance, subsequent overﬁltration, and then
hypotony.36 Also, thin blebs are prone to leakage and subsequent
development of blebitis or endophthalmitis. Sharan et al reported
a 0.96% bleb infection rate with a 5.3-year mean follow-up.37 Bleb
leakage, black race, and bleb manipulation were risk factors for
infection. In a retrospective review study of trabeculectomy with
MMC, bleb infections occurred in six of 233 (2.6%) eyes, and average
postoperative time until infection was 24.7 months.38 In our case
series, only one eye (0.7%) developed bleb leakage, and did so 19
months after trabeculectomy with concurrent 0.2 mg/mL MMC
soaking for 3 minutes; this condition resulted in endophthalmitis.
It is difﬁcult to identify the cause of cataract progression as
either surgery- or aging-related. In eyes with cataract progression
within 1 year after trabeculectomy requiring extraction, theconditionwas considered to be possibly related to surgery or MMC.
In our study, cataract progression with extraction within 1 year
after trabeculectomy was noted in three eyes (2.0%). In a similar
study of 60 eyes which received MMC-augmented trabeculectomy,
only one eye (1.7%) required cataract surgery at 1-year follow-up.39
In another study, there was no difference in cataract progression or
cataract surgery between MMC-treated trabeculectomy and the
control group.40
Taking into consideration the eyes with rather severe compli-
cations, such as wound gap with leakage after 5 postoperative days,
hypotony, hypotony maculopathy, choroidal detachment, over-
hanging bleb, bleb leakage, and endophthalmitis (n ¼ 26, 17.7%),
there is no signiﬁcant difference when comparing with other eyes
in relation to different MMC amount, deﬁned as MMC concentra-
tion multiplied by application duration (p ¼ 0.136; Table 6). In the
literature, a doseeresponse relationship seems to exist between
MMC application (including the concentration and duration of
exposure) and surgical results (including IOP lowering effect and
complications).20,29 In our study, due to variable MMC concentra-
tion and duration, we deﬁned MMC amount as mentioned above.
However, whether the effects caused by, for example, 0.1 mg/mL for
2 minutes and 0.2 mg/mL for 1 minute, are the same or not require
further elucidation. It is possible that factors other than MMC
amount, such as patient’s age or eye condition, play a role in the
development of complications.
Trabeculectomy has been the most favored form of glaucoma
surgery for more than 40 years. Antiﬁbrotic agent-assisted trabe-
culectomy is a well-developed surgical technique for enhancing
surgical results, and methods for decreasing related complications
are currently being sought. In addition to traditional chemical
drugs, the advent of new technologies, such as dendrimers, anti-
bodies, aptamers, ribozymes, gene therapy with viral vectors, and
RNA interference, has opened the door to an entirely new genera-
tion of therapies for preventing ﬁbrosis after glaucoma surgery.415. Conclusion
The outcome of trabeculectomy with low-dose intraoperative
mitomycin is favorable in primary glaucoma patients at 2-year
follow-up. Complications related to concurrent MMC application
are still an important issue. Severe complications are not signiﬁ-
cantly related to MMC amount. Factors associated with severe
complications require further study. Gentle intraoperative manip-
ulation with minimal tissue damage is essential for decreased scar
formation and for minimizing subsequent surgical failure. Careful
selection of MMC concentration and application time based on
preoperative and intraoperative risk factors may further improve
surgical results.References
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